Clinical Trial

Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension

Study acronym: AIPHY
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 8, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated. Artificial intelligence is used to study and develop theories and methods that simulate and extend human intelligence, which is being applied in fields related to cardiovascular diseases. The study intends to combine multimodal clinical data of patients who undergo right heart catheterization at Fuwai Hospital with artificial intelligence techniques to create programs that can screen and diagnose pulmonary hypertension.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-09-30; most recent amendment 2025-04-06.
Trial Details
NCT Number NCT05566002
Lead Sponsor Chinese Pulmonary Vascular Disease Research Group
Conditions Pulmonary Hypertension, Pulmonary Arterial Hypertension
Enrollment 2,000 participants
Start Date 2022-06-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-08